

# Transitional Pass-Through Payment for SINUVA



UPDATED July 1, 2020

SINUVA was granted transitional pass-through status, effective July 1, 2020, and assigned a new **C-Code of C9122**. When a drug is granted pass-through status by CMS, ambulatory surgery centers and other outpatient facilities are eligible to receive separate payment for the pass-through drug in addition to the payment received for procedures furnished during the patient encounter.

Pass-through status remains in effect for 3 years, and is applicable to **Medicare Fee-for-Service patients only**.

When billing Medicare, **C9122** and the corresponding NDC number **10599000301** (mometasone furoate, sinus implant 10mcg) should be billed on the claim form and report the CPT code(s) which most accurately describe the services performed in association with the placement of a drug eluting sinus implant.

AMBULATORY SURGERY CENTER/ HOSPITAL OUTPATIENT SURGERY CODE	NDC NUMBER	BILLING UNITS	DESCRIPTOR
C9122	10599000301	1 unit for every 10 mcg = 135 billing units	Mometasone furoate sinus implant, 10mcg, Pass through status code for use with Fee For Service Medicare Patients only

## DISCLAIMER

This is not a guarantee of payment, coverage, or reimbursement. Intersect ENT does not provide any advice, recommendation, guarantee, or warranty relating to coverage, reimbursement, or coding for any product or service. Healthcare providers are responsible for determining coverage and reimbursement information and ensuring the accuracy and completeness of claim submissions for their patients. Coding, coverage, and reimbursement vary significantly by payer, patient, and setting of care and are subject to change. Additional information may exist. Actual coverage and reimbursement decisions are made by individual payers. Healthcare providers are responsible for consulting payers' policies.

For more information on reimbursement or billing pertaining to the pass-through status of SINUVA please contact your Regional Reimbursement Director at Intersect ENT. To enroll a patient and check benefits contact Connect at 833-4SINUVA. To procure SINUVA please contact McKesson Specialty or ASD Healthcare directly.

For additional support or questions, please visit [SINUVA.com](https://www.sinuva.com) or contact Connect by phone at 1-833-4-SINUVA (1-833-474-6882).

## INDICATION

SINUVA is a corticosteroid-eluting (mometasone furoate) implant indicated for the treatment of nasal polyps, in patients  $\geq 18$  years of age who have had ethmoid sinus surgery.

## IMPORTANT SAFETY INFORMATION

### CONTRAINDICATIONS

Patients with known hypersensitivity to mometasone furoate and any of the ingredients of the SINUVA Sinus Implant.

### WARNINGS AND PRECAUTIONS

**Local Effects:** Monitor nasal mucosa adjacent to the SINUVA Sinus Implant for any signs of bleeding (epistaxis), irritation, infection, or perforation. Avoid use in patients with nasal ulcers or trauma.

**Ocular Effects:** Monitor patients with a change in vision or with a history of increased intraocular pressure, glaucoma, and/or cataracts closely.

**Hypersensitivity Reactions:** Hypersensitivity reactions, including rash, pruritus, and angioedema have been reported with the use of corticosteroids.

**Immunosuppression:** Persons who are using drugs that suppress the immune system are more susceptible to infections than healthy individuals. Corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infection of the respiratory tract; untreated systemic fungal, bacterial, viral, or parasitic infections; or ocular herpes simplex.

**Hypercorticism and Adrenal Suppression:** If corticosteroid effects such as hypercorticism and adrenal suppression appear in patients, consider sinus implant removal.

### ADVERSE REACTIONS

The most common adverse reactions observed ( $> 1\%$  of subjects and that occurred more frequently in the treatment group compared to control) in clinical studies were asthma, headache, epistaxis, presyncope, bronchitis, otitis media, and nasopharyngitis.

### POSTMARKETING EXPERIENCE

The following adverse reactions have been identified during post-approval use of the SINUVA sinus implant. These events include implant migration, lack of efficacy, nasal pain, headache, epistaxis.

**Rx only. Please see attached Full Prescribing Information for SINUVA also available at [SINUVA.com/PI](https://www.sinuva.com/PI)**



Intersect ENT and SINUVA are registered trademarks of Intersect ENT, Inc. in the United States and other countries.  
©2020 Intersect ENT, Inc. All rights reserved. MPM-11838 Rev. 1.0

